Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Masitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 13/20 | 0.94 |
| ▸ | PDGFRA known ✓ | P16234 | 4/20 | 0.94 |
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.94 |
| ▸ | ABL1 | P00519 | 19/20 | 0.94 |
| ▸ | BCR | P11274 | 14/20 | 0.94 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | SRC | P12931 | 3/20 | 0.94 |
| ▸ | EGFR | P00533 | 2/20 | 0.94 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.94 |
| ▸ | LCK | P06239 | 2/20 | 0.94 |
| ▸ | FYN | P06241 | 2/20 | 0.94 |
| ▸ | CSF1R | P07333 | 2/20 | 0.94 |
| ▸ | LYN | P07948 | 2/20 | 0.94 |
| ▸ | FGR | P09769 | 2/20 | 0.94 |
| ▸ | BRAF | P15056 | 2/20 | 0.94 |
| ▸ | NQO2 | P16083 | 2/20 | 0.94 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.94 |
| ▸ | FRK | P42685 | 2/20 | 0.94 |
| ▸ | BLK | P51451 | 2/20 | 0.94 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Masitinib SCHEMBL30024483 | 1.00 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL1096348 | 1.00 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL29353195 | 0.97 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL29355443 | 0.97 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL717239 | 0.97 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL5515053 | 0.93 | ABL1 (0.84) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL3301373 | 0.93 | ABL1 (0.91) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL16085058 | 0.91 | ABL1 (0.89) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL717173 | 0.91 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL17177780 | 0.91 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8450302-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302577-A1 | TREATMENT OF GIST WITH MASITINIB | AB SCIENCE (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20110201620-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201620-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | KIT, ABL1, MUSK | KIT 1/4885PDGFRA 52/4885PDGFRB 89/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KIT 711/4885PDGFRA 889/4885PDGFRB 683/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KIT 623/4885PDGFRA 1052/4885PDGFRB 779/4885 |
| US-20120302577-A1 | TREATMENT OF GIST WITH MASITINIB | ABL1, KIT, MYLK | KIT 2/4885PDGFRA 41/4885PDGFRB 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.